164 related articles for article (PubMed ID: 38397992)
1. Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
Caminati M; Maule M; Benoni R; Bagnasco D; Beghè B; Braido F; Brussino L; Cameli P; Candeliere MG; Carpagnano GE; Costanzo G; Crimi C; D'Amato M; Del Giacco S; Guarnieri G; Yacoub MR; Micheletto C; Nicola S; Olivieri B; Pini L; Schiappoli M; Vaia R; Vianello A; Visca D; Spanevello A; Senna G
Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38397992
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
[TBL] [Abstract][Full Text] [Related]
3. Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab.
Paoletti G; Casini M; Malvezzi L; Pirola F; Russo E; Nappi E; Muci GQ; Montagna C; Messina MR; Ferri S; Racca F; Lamacchia D; Cataldo G; Puggioni F; De Virgilio A; Ferreli F; Mercante G; Spriano G; Canonica GW; Heffler E
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):457-463. PubMed ID: 38095494
[TBL] [Abstract][Full Text] [Related]
4. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
6. Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
Al-Ahmad M; Ali A; Khalaf M; Alterki A; Rodriguez-Bouza T
BMC Pulm Med; 2023 Jul; 23(1):266. PubMed ID: 37464395
[TBL] [Abstract][Full Text] [Related]
7. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics.
Förster-Ruhrmann U; Stergioudi D; Szczepek AJ; Fluhr JW; Zuberbier T; Olze H; Bergmann KC
World Allergy Organ J; 2023 Feb; 16(2):100746. PubMed ID: 36852411
[TBL] [Abstract][Full Text] [Related]
8. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
10. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management.
Carpagnano GE; Scioscia G; Buonamico E; Lacedonia D; Diaferia F; Capozza E; Lepore G; Resta O; Foschino Barbaro MP
Multidiscip Respir Med; 2022 Jan; 17(1):797. PubMed ID: 35280851
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma.
Gurnell M; Radwan A; Bachert C; Lugogo N; Cho SH; Nash S; Zhang H; Khan AH; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2024; 17():1-8. PubMed ID: 38250137
[TBL] [Abstract][Full Text] [Related]
12. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
Hardison SA; Senior BA
J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):64. PubMed ID: 37759322
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E; Pasquini E; Trimarchi M; La Mantia I; Pagella F; Ottaviano G; Garzaro M; Pipolo C; Torretta S; Seccia V; Cantone E; Ciofalo A; Lucidi D; Fadda GL; Pafundi PC; Settimi S; Montuori C; Anastasi F; Pagliuca G; Ghidini A; Cavaliere C; Maffei M; Bussu F; Gallo S; Canevari FRM; Paludetti G; Galli J;
Allergy; 2023 Oct; 78(10):2669-2683. PubMed ID: 37203259
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life.
Nettis E; Brussino L; Patella V; Bonzano L; Detoraki A; Di Leo E; Sirufo MM; Caruso C; Lodi Rizzini F; Conte M; Yacoub MR; Triggiani M; Ridolo E; Macchia L; Rolla G; Brancaccio R; De Paulis A; Spadaro G; Di Bona D; D'Uggento AM; Ginaldi L; Gaeta F; Nucera E; Jaubashi K; Villalta D; Dagna L; Ciotta D; Pucciarini F; Bagnasco D; Celi G; Chieco Bianchi F; Cosmi L; Costantino MT; Crivellaro MA; D'Alò S; Del Biondo P; Del Giacco S; Di Gioacchino M; Di Pietro L; Favero E; Gangemi S; Guarnieri G; Heffler E; Leto Barone MS; Lombardo C; Losa F; Matucci A; Minciullo PL; Parronchi P; Passalacqua G; Pucci S; Rossi O; Salvati L; Schiappoli M; Senna G; Vianello A; Vultaggio A; Baoran Y; Incorvaia C; Canonica GW
Clin Mol Allergy; 2022 May; 20(1):6. PubMed ID: 35590407
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
18. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP.
Minagawa S; Araya J; Watanabe N; Fujimoto S; Watanabe J; Hara H; Numata T; Kuwano K; Matsuwaki Y
BMC Pulm Med; 2022 Jun; 22(1):258. PubMed ID: 35764984
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dupilumab in real-life settings: a STROBE study.
Gal A; Gravier-Dumonceau R; Penicaud M; Ebode D; Radulesco T; Michel J
Eur Arch Otorhinolaryngol; 2024 Mar; ():. PubMed ID: 38498194
[TBL] [Abstract][Full Text] [Related]
20. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps.
Siddiqui S; Bachert C; Chaker AM; Han JK; Hellings PW; Peters AT; Heffler E; Kamat S; Zhang H; Nash S; Khan AH; De Prado Gomez L; Jacob-Nara JA; Rowe PJ; Deniz Y
ERJ Open Res; 2022 Oct; 8(4):. PubMed ID: 36451848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
